Augmentation of Serotonergic Agent to Brintellix?

I just read "Electrophysiological Investigations on the Role of Selected Serotonin Receptors and
the Serotonin Transporter on Serotonin Transmission in the Rat Brain" which is a study by
Maurice Lecours who works at the University of Ottawa, Institute of Mental Health Research.
I found his research to be fascinating. I am actually on Day X of my Brintellix (vortioxetine)
prescription; however, for the past X days, I have been administering 20mg. vortioxetine
1TPOQAMCF in place of my prior 10mg. trial. I have only had a partial remission of my
symptoms with this medication. I'm not so sure if I'd follow the suggestion of my own thread
title, but I was wondering what everybody thought about the following excerpts paralleled to
patients like myself that have not responded adequately to vortioxetine monotherapy for MDD?:
"These findings indicate that either the co-administration of an SSRI in addition to a 5-HT3
receptor antagonist or a multimodal agent that acts as a SSRI and 5-HT3 receptor, such as
vortioxetine, could enhance 5-HT neurotransmission to produce AD and antiemesis effects,
similar to that of litoxetine, after long-term administration."
Lecours seems to suggest that augmentation of a classical SSRI to vortioxetine may be a good
idea because you have to keep this in mind (also excerpted from the study):
"selective 5-HT agents alone, such as escitalopram, and multimodal agents, such as vortioxetine,
alter 5-HT neurotransmission through different receptors and exert different actions, via
transporter and/or receptor activity, on the serotonergic system in the hippocampus consistent
with other antidepressant strategies and with a unique pharmacological profile."
Supplementary, compared to other SSRIs, this study revealed: "vortioxetine has a low occupancy
for the 5-HTT, escitalopram was used at a dose of 5 mg/kg in order to better mimic the effects of
low occupancy alone."
I'm suggesting, based upon these excerpts that I've provided from Lecours' study, that
augmentation of a traditional SSRI would perhaps enhance vortioxetine's unique
pharmacological effects for patients that are diagnosed with MDD? Perhaps aggrandizing
Brintellix with a typical SSRI, or even a TCA, could theoretically provide a more potent
antidepressant/anxiolytic response for patients prescribed Brintellix that are not responsive or
were not able to achieve full remission of their symptomatic depression?